Last reviewed 2026-04-22 · How we verify

Basalin to Lantus

Nanjing First Hospital, Nanjing Medical University · FDA-approved active Small molecule

Basalin to Lantus is a Long-acting basal insulin analog Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Basalin is a long-acting basal insulin analog that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.

Basalin is a long-acting basal insulin analog that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic name	Basalin to Lantus
Sponsor	Nanjing First Hospital, Nanjing Medical University
Drug class	Long-acting basal insulin analog
Target	Insulin receptor
Modality	Small molecule
Therapeutic area	Diabetes
Phase	FDA-approved

Mechanism of action

Basalin (insulin glargine) is a recombinant human insulin analog designed to provide steady, long-acting basal insulin coverage for 24 hours. It binds to insulin receptors on muscle and adipose tissue, facilitating glucose uptake and glycogen synthesis while suppressing hepatic glucose production. This mimics the physiological basal insulin secretion pattern in non-diabetic individuals.

Approved indications

Type 1 diabetes mellitus
Type 2 diabetes mellitus

Common side effects

Hypoglycemia
Injection site reactions
Weight gain
Lipodystrophy

Key clinical trials

Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Basalin to Lantus CI brief — competitive landscape report
Basalin to Lantus updates RSS · CI watch RSS
Nanjing First Hospital, Nanjing Medical University portfolio CI

Frequently asked questions about Basalin to Lantus

What is Basalin to Lantus?

Basalin to Lantus is a Long-acting basal insulin analog drug developed by Nanjing First Hospital, Nanjing Medical University, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does Basalin to Lantus work?

Basalin is a long-acting basal insulin analog that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.

What is Basalin to Lantus used for?

Basalin to Lantus is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes Basalin to Lantus?

Basalin to Lantus is developed and marketed by Nanjing First Hospital, Nanjing Medical University (see full Nanjing First Hospital, Nanjing Medical University pipeline at /company/nanjing-first-hospital-nanjing-medical-university).

What drug class is Basalin to Lantus in?

Basalin to Lantus belongs to the Long-acting basal insulin analog class. See all Long-acting basal insulin analog drugs at /class/long-acting-basal-insulin-analog.

What development phase is Basalin to Lantus in?

Basalin to Lantus is FDA-approved (marketed).

What are the side effects of Basalin to Lantus?

Common side effects of Basalin to Lantus include Hypoglycemia, Injection site reactions, Weight gain, Lipodystrophy.

What does Basalin to Lantus target?

Basalin to Lantus targets Insulin receptor and is a Long-acting basal insulin analog.

Drug class: All Long-acting basal insulin analog drugs
Target: All drugs targeting Insulin receptor
Manufacturer: Nanjing First Hospital, Nanjing Medical University — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 1 diabetes mellitus
Indication: Drugs for Type 2 diabetes mellitus

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing